{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:27:28Z","timestamp":1773692848754,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.toxicon.2018.01.018","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:19:51Z","timestamp":1517404791000},"page":"100-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity \u2013 Insights from recent studies"],"prefix":"10.1016","volume":"147","author":[{"given":"J\u00f6rg","family":"Wissel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2018.01.018_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fneur.2017.00018","article-title":"How many dystonias? Clinical evidence","volume":"8","author":"Albanese","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib2","first-page":"2201","article-title":"Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement","volume":"262","author":"Albanese","year":"2015","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mds.25475","article-title":"Phenomenology and classification of dystonia: a consensus update","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2018.01.018_bib4","series-title":"Highlights of Prescribing Information - Botox\u00ae","author":"Allergan Inc","year":"2017"},{"key":"10.1016\/j.toxicon.2018.01.018_bib5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1177\/0269215513491274","article-title":"The efficacy of botulinum toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach","volume":"27","author":"Baker","year":"2013","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.018_bib6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00702-015-1384-6","article-title":"High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis","volume":"122","author":"Baricich","year":"2015","journal-title":"J.\u00a0Neural Transm. Vienna"},{"key":"10.1016\/j.toxicon.2018.01.018_bib7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2014.925462","article-title":"Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians)","volume":"17","author":"Bensmail","year":"2014","journal-title":"J.\u00a0Med. Econ."},{"key":"10.1016\/j.toxicon.2018.01.018_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2018.01.018_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.toxicon.2018.01.018_bib10","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1073\/pnas.96.6.3200","article-title":"Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals","volume":"96","author":"de Paiva","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.toxicon.2018.01.018_bib11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.0b013e31829bfdf6","article-title":"Development and validation of a clinical guideline for diagnosing blepharospasm","volume":"81","author":"Defazio","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.018_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pmrj.2011.10.001","article-title":"Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity","volume":"4","author":"Doan","year":"2012","journal-title":"PM. R."},{"key":"10.1016\/j.toxicon.2018.01.018_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.23736\/S1973-9087.16.04329-X","article-title":"Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis","volume":"53","author":"Dong","year":"2017","journal-title":"Eur. J. Phys. Rehabil. Med."},{"key":"10.1016\/j.toxicon.2018.01.018_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum toxin: mechanisms of action","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00702-014-1252-9","article-title":"Safety aspects of incobotulinumtoxinA high-dose therapy","volume":"122","author":"Dressler","year":"2015","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.toxicon.2018.01.018_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009358","article-title":"Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study","volume":"5","author":"Dressler","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.toxicon.2018.01.018_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00702-014-1253-8","article-title":"Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects","volume":"122","author":"Dressler","year":"2015","journal-title":"J.\u00a0Neural. Transm. Vienna"},{"key":"10.1016\/j.toxicon.2018.01.018_bib18","first-page":"787","article-title":"A\u00a0prevalence study of primary dystonia in eight European countries","volume":"247","author":"Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group","year":"2000","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.pmrj.2017.02.014","article-title":"OnabotulinumtoxinA for lower limb spasticity: guidance from a Delphi panel approach","volume":"9","author":"Esquenazi","year":"2017","journal-title":"PM. R"},{"key":"10.1016\/j.toxicon.2018.01.018_bib20","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A\u00a0randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin\u00ae) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.toxicon.2018.01.018_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jns.2014.08.004","article-title":"IncobotulinumtoxinA (Xeomin\u00ae) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated","volume":"346","author":"Evidente","year":"2014","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.toxicon.2018.01.018_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12955-015-0340-3","article-title":"The negative impact of spasticity on the health-related quality of life of stroke survivors: a longitudinal cohort study","volume":"13","author":"Gillard","year":"2015","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.toxicon.2018.01.018_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.apmr.2008.04.030","article-title":"Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study","volume":"90","author":"Gracies","year":"2009","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.018_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9","author":"Greene","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2018.01.018_bib25","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.toxicon.2008.12.008","article-title":"Treatment of focal dystonias with botulinum neurotoxin","volume":"54","author":"Hallett","year":"2009","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.01.018_bib26","first-page":"e47","article-title":"Physician characteristics in an international, non-interventional study of botulinum toxin formulations in treatment-na\u00efve patients with spasticity (SPACE)","volume":"57","author":"Harriss","year":"2014","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"10.1016\/j.toxicon.2018.01.018_bib27","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.toxicon.2016.11.107","article-title":"SPAsticity in PractiCE (SPACE): an international, observational study of botulinum toxin type A in spasticity","volume":"123","author":"Harriss","year":"2016","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.01.018_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001853","article-title":"An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)","volume":"3","author":"Hefter","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.toxicon.2018.01.018_bib29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.68.6.707","article-title":"Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study","volume":"68","author":"Hyman","year":"2000","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2018.01.018_bib30","first-page":"515","article-title":"High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy","volume":"34","author":"Intiso","year":"2014","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.toxicon.2018.01.018_bib31","series-title":"Highlights of Prescribing Information - Dysport\u00ae","author":"Ipsen Biopharm Ltd","year":"2017"},{"key":"10.1016\/j.toxicon.2018.01.018_bib32","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.018_bib33","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.018_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity","volume":"43","author":"Ka\u0148ovsk\u00fd","year":"2011","journal-title":"J.\u00a0Rehabil. Med."},{"key":"10.1016\/j.toxicon.2018.01.018_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","article-title":"Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity","volume":"32","author":"Ka\u0148ovsk\u00fd","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib36","first-page":"265","article-title":"Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency","volume":"246","author":"Kessler","year":"1999","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib37","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2522\/ptj.20130408","article-title":"Rehabilitation therapies after botulinum toxin-A injection to manage limb spasticity: a systematic review","volume":"94","author":"Kinnear","year":"2014","journal-title":"Phys. Ther."},{"key":"10.1016\/j.toxicon.2018.01.018_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0035-1571215","article-title":"The botulinum toxin as a therapeutic agent: molecular structure and mechanism of action in motor and sensory systems","volume":"36","author":"Kumar","year":"2016","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib39","series-title":"Spasticity: Disordered Motor Control","first-page":"485","article-title":"Symposium synopsis in","author":"Lance","year":"1980"},{"key":"10.1016\/j.toxicon.2018.01.018_bib40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2377-14-91","article-title":"Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia","volume":"14","author":"Marsh","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib41","series-title":"Highlights of Prescribing Information \u2013 Xeomin\u00ae","author":"Merz Pharmaceuticals LLC","year":"2015"},{"key":"10.1016\/j.toxicon.2018.01.018_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1179\/016164109X12478302362734","article-title":"Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients","volume":"32","author":"Mohammadi","year":"2010","journal-title":"Neurol. Res."},{"key":"10.1016\/j.toxicon.2018.01.018_bib43","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079904125003962","article-title":"Safety of botulinum toxin type A: a systematic review and meta-analysis","volume":"20","author":"Naumann","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.toxicon.2018.01.018_bib44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09638280400014576","article-title":"Spasticity: clinical perceptions, neurological realities and meaningful measurement","volume":"27","author":"Pandyan","year":"2005","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.018_bib45","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1474-4422(11)70232-0","article-title":"Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis","volume":"10","author":"Phukan","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/0269215513497735","article-title":"Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques","volume":"28","author":"Picelli","year":"2014","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.018_bib47","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/PHM.0b013e318269d7f3","article-title":"Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques","volume":"91","author":"Picelli","year":"2012","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.018_bib48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000069495","article-title":"A\u00a0double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport\u00ae) in the treatment of spastic equinovarus deformity after stroke","volume":"15","author":"Pittock","year":"2003","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.toxicon.2018.01.018_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport","volume":"64","author":"Poewe","year":"1998","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2018.01.018_bib50","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2147\/PPA.S106560","article-title":"Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia","volume":"10","author":"Poliziani","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.toxicon.2018.01.018_bib51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13561-016-0107-5","article-title":"Quality of life and costs of spasticity treatment in German stroke patients","volume":"6","author":"Rychlik","year":"2016","journal-title":"Health Econ. Rev."},{"key":"10.1016\/j.toxicon.2018.01.018_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2015.01.033","article-title":"Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke","volume":"350","author":"Santamato","year":"2015","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.toxicon.2018.01.018_bib53","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00702-012-0892-x","article-title":"Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke","volume":"120","author":"Santamato","year":"2013","journal-title":"J.\u00a0Neural Transm. Vienna"},{"key":"10.1016\/j.toxicon.2018.01.018_bib54","first-page":"521","article-title":"Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry","volume":"121","author":"Schramm","year":"2014","journal-title":"J.\u00a0Neural Transm. Vienna"},{"key":"10.1016\/j.toxicon.2018.01.018_bib55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J.\u00a0Med. Econ."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.toxicon.2018.01.018_bib56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1468-1331.2010.03129.x","article-title":"Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement","volume":"17","author":"Sheean","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2018.01.018_bib57","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.018_bib58","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pmrj.2016.06.016","article-title":"OnabotulinumtoxinA injection for poststroke upper-limb spasticity: guidance for early injectors from a Delphi panel process","volume":"9","author":"Simpson","year":"2017","journal-title":"PM. R."},{"key":"10.1016\/j.toxicon.2018.01.018_bib59","series-title":"Myobloc\u00ae FDA-approved Labelling","author":"Solstice Neurosciences Inc","year":"2009"},{"key":"10.1016\/j.toxicon.2018.01.018_bib60","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/354906","article-title":"Pathophysiology of spasticity: implications for neurorehabilitation","volume":"2014","author":"Trompetto","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.toxicon.2018.01.018_bib61","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","article-title":"Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm","volume":"120","author":"Truong","year":"2013","journal-title":"J.\u00a0Neural Transm. Vienna"},{"key":"10.1016\/j.toxicon.2018.01.018_bib62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1191\/0269215502cr512oa","article-title":"Prevalence of spasticity post stroke","volume":"16","author":"Watkins","year":"2002","journal-title":"Clin. Rehabil."},{"key":"10.1016\/j.toxicon.2018.01.018_bib63","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1212\/WNL.0000000000003789","article-title":"Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study","volume":"88","author":"Wissel","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2018.01.018_bib64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2340\/16501977-0303","article-title":"European consensus table on the use of botulinum toxin type A in adult spasticity","volume":"41","author":"Wissel","year":"2009","journal-title":"J.\u00a0Rehabil. Med."},{"key":"10.1016\/j.toxicon.2018.01.018_bib65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/mds.23426","article-title":"Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis","volume":"26","author":"Yablon","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2018.01.018_bib66","first-page":"S12","article-title":"Spasticity: a review","volume":"44","author":"Young","year":"1994","journal-title":"Neurology"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118300321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118300321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:10:28Z","timestamp":1758575428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010118300321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":66,"alternative-id":["S0041010118300321"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.01.018","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity \u2013 Insights from recent studies","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}